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Background: We sought to investigate the prognostic importance of plasma myeloperoxidase (MPO) levels in patients with STEMI at long term 
follow-up period and to analyze the correlation of plasma MPO levels with other biochemical parameters.
Methods: We evaluated plasma MPO levels in 73 consecutive patients (56 men, mean age; 56 ± 11 years) diagnosed with acute ST elevation 
myocardial infarction and 46 age- and sex- matched healthy controls. The median plasma MPO levels of the patients were 68 ng/ml. Patients were 
classified into 2 groups according to the median MPO value (Group 1: plasma MPO ≤68 ng/ml and Group 2: plasma MPO >68 ng/ml). Patients 
were monitored for the occurrence of major adverse cardiovascular events (MACE). MACE were defined as cardiac death, reinfarction, new hospital 
admission for angina, heart failure and revascularization procedures.
Results: Mean follow-up period was 25 ± 16 months. Plasma MPO levels were higher in STEMI patients than the subjects in control group (82 ± 
34 ng/ml vs 20 ± 12 ng/ml p = 0.001). Patients with high MPO levels were more likely to have anterior wall myocardial infarction, low LVEF and 
multi-vessel coronary artery disease than those with low plasma MPO levels. Composite MACE occurred in twelve of the patients with high MPO levels 
(33%) and four of the patients with low MPO levels (11%) (p=0.020). The incidences of nonfatal recurrent myocardial infarction and verified cardiac 
death were higher in the high MPO levels group. At multivariate analysis, high plasma MPO levels were independent predictors of MACE [odds ratio 
(OR) 3.843, <95% CI 1.625-6.563; p = 0.003] together with CRP (OR 2.863, 95% CI 1.337-6.452; p = 0.012) and LVEF <40% (OR 3.225, 95% CI 
1.434-6.554; p = 0.001). Plasma MPO levels were also correlated with CRP levels (r=0.451, p=0.004), troponin T (r=0.390, p=0.004), and NT pro 
BNP levels (r=0.445, p=0.002) but not with WBC count (r=0.166, p=0.189) in the STEMI patients.
Conclusions: High plasma MPO levels identify patients with a worse prognosis after STEMI at two-year follow up period. Evaluation of plasma 
MPO levels may be useful in determining patients at high risk of death and MACE, who might benefit from a further aggressive treatment and closer 
follow-up.
